CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
Status:
Terminated
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of 29 intravenous infusions of CER-001 vs.
placebo, given at weekly (9 infusions) and biweekly (20 infusions) intervals on carotid
vessel wall area as measured by 3TMRI, when administered to patients with familial primary
hypoalphalipoproteinemia with proven CVD and appropriate background lipid-lowering therapy.